{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AIN457+%28secukinumab%29",
    "query": {
      "intervention": "AIN457 (secukinumab)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 70,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AIN457+%28secukinumab%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T17:20:52.654Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01250171",
      "title": "The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Secukinumab 10 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Canakinumab 10 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 72,
      "start_date": "2010-11",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2013-01-07",
      "last_synced_at": "2026-10-01T17:20:52.654Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01250171"
    },
    {
      "nct_id": "NCT04179175",
      "title": "Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "secukinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 702,
      "start_date": "2020-03-18",
      "completion_date": "2026-07-15",
      "has_results": true,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-01T17:20:52.654Z",
      "location_count": 29,
      "location_summary": "Rogers, Arkansas • San Diego, California • Whittier, California + 22 more",
      "locations": [
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04179175"
    },
    {
      "nct_id": "NCT02404350",
      "title": "Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Secukinumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 997,
      "start_date": "2015-08-31",
      "completion_date": "2019-01-24",
      "has_results": true,
      "last_update_posted_date": "2020-04-20",
      "last_synced_at": "2026-10-01T17:20:52.654Z",
      "location_count": 22,
      "location_summary": "Upland, California • Aurora, Colorado • Denver, Colorado + 16 more",
      "locations": [
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02404350"
    },
    {
      "nct_id": "NCT01649375",
      "title": "16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anklyosing Spondylitis"
      ],
      "interventions": [
        {
          "name": "Secukinumab (75 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab (150 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 219,
      "start_date": "2012-10-18",
      "completion_date": "2018-09-18",
      "has_results": true,
      "last_update_posted_date": "2019-10-30",
      "last_synced_at": "2026-10-01T17:20:52.654Z",
      "location_count": 10,
      "location_summary": "Mesa, Arizona • Upland, California • Edina, Minnesota + 6 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Edina",
          "state": "Minnesota"
        },
        {
          "city": "Tupelo",
          "state": "Mississippi"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01649375"
    },
    {
      "nct_id": "NCT01863732",
      "title": "Extension in AS: Sustainability of Benefits, Safety and Tolerability",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spondylitis, Ankylosing"
      ],
      "interventions": [
        {
          "name": "Secukinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Pbo)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 274,
      "start_date": "2013-11-06",
      "completion_date": "2018-03-16",
      "has_results": true,
      "last_update_posted_date": "2019-07-30",
      "last_synced_at": "2026-10-01T17:20:52.654Z",
      "location_count": 5,
      "location_summary": "Portland, Oregon • Duncansville, Pennsylvania • Jackson, Tennessee + 2 more",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        },
        {
          "city": "Jackson",
          "state": "Tennessee"
        },
        {
          "city": "Kingsport",
          "state": "Tennessee"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01863732"
    },
    {
      "nct_id": "NCT00669942",
      "title": "Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "AIN457",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 104,
      "start_date": "2005-12",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2015-03-30",
      "last_synced_at": "2026-10-01T17:20:52.654Z",
      "location_count": 12,
      "location_summary": "Anniston, Alabama • Tucson, Arizona • Largo, Florida + 9 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Palm Harbor",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00669942"
    },
    {
      "nct_id": "NCT02798211",
      "title": "Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Secukinumab 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2016-06-27",
      "completion_date": "2018-12-05",
      "has_results": true,
      "last_update_posted_date": "2021-10-07",
      "last_synced_at": "2026-10-01T17:20:52.654Z",
      "location_count": 57,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02798211"
    },
    {
      "nct_id": "NCT00995709",
      "title": "Phase III Study in Refractory Behcet's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Behcet Disease"
      ],
      "interventions": [
        {
          "name": "AIN457",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2009-10",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2015-08-31",
      "last_synced_at": "2026-10-01T17:20:52.654Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Arlington, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Arlington",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00995709"
    },
    {
      "nct_id": "NCT01359943",
      "title": "Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "secukinumab (AIN457)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 221,
      "start_date": "2011-10",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2015-03-02",
      "last_synced_at": "2026-10-01T17:20:52.654Z",
      "location_count": 8,
      "location_summary": "Vestavia Hills, Alabama • Peoria, Arizona • Upland, California + 5 more",
      "locations": [
        {
          "city": "Vestavia Hills",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Bowling Green",
          "state": "Kentucky"
        },
        {
          "city": "Tupelo",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01359943"
    },
    {
      "nct_id": "NCT01806597",
      "title": "Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate to Severe Palmoplantar Psoriasis"
      ],
      "interventions": [
        {
          "name": "secukinumab 150 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "secukinumab 300 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2013-06-19",
      "completion_date": "2016-11-02",
      "has_results": true,
      "last_update_posted_date": "2018-02-22",
      "last_synced_at": "2026-10-01T17:20:52.654Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01806597"
    }
  ]
}